Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same author

Is supplemental vitamin D useful in the clinically isolated syndrome (CIS) typical of multiple sclerosis?

Expert opinion on pharmacotherapy·2026
Same author

Is seltorexant, an orexin-2 receptor antagonist, showing promise in insomnia?

Expert opinion on investigational drugs·2026
Same author

Does varenicline promote abstinence in youths who vape?

Expert opinion on pharmacotherapy·2025
Same author

Reply to: reframing guselkumab's benefit in ulcerative colitis: insights from QUASAR and emerging evidence.

Expert opinion on biological therapy·2025
Same author

With guselkumab, does the dual mechanisms to inhibit IL-23, help in ulcerative colitis?

Expert opinion on biological therapy·2025

Related Experiment Videos

Does rosiglitazone increase cardiovascular outcomes?

Sheila A Doggrell1

  • 1Doggrell Biomedical Communications, 14 Quandong Crescent, Nightcliff, NT 0810, Australia. sheila.doggrell@bigpond.com

Expert Opinion on Pharmacotherapy
|October 13, 2007
PubMed
Summary

Rosiglitazone, used for Type 2 diabetes, may have a small harmful effect on cardiovascular outcomes. Further trials are needed to definitively assess its safety and optimal use.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Rosiglitazone is a widely prescribed medication for Type 2 diabetes.
  • Concerns regarding its cardiovascular safety have prompted recent evaluations.

Purpose of the Study:

  • To evaluate the cardiovascular outcomes associated with rosiglitazone use in Type 2 diabetes patients.
  • To address the safety concerns arising from initial meta-analyses.

Main Methods:

  • A meta-analysis of 42 short-term trials not designed for cardiovascular outcome assessment.
  • Interim analysis of the long-term RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycaemia in Diabetes) trial.

Main Results:

  • The meta-analysis indicated a statistically significant increase in myocardial infarctions (OR 1.43, p=0.03) with rosiglitazone.

Related Experiment Videos

  • The RECORD trial interim analysis showed no significant difference in cardiovascular events between rosiglitazone and control groups (9.8% vs 9.1%).
  • Both analyses presented limitations, necessitating further investigation.

    • Conclusions:

    • Rosiglitazone may potentially have a small detrimental effect on cardiovascular outcomes.
    • The observed effect, if present, is likely small and warrants further research for definitive conclusions.
    • Additional large-scale trials are recommended to unequivocally determine rosiglitazone's cardiovascular impact and guide its clinical use.